These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 29955666)
1. Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. Gold M; Amatniek J; Carrillo MC; Cedarbaum JM; Hendrix JA; Miller BB; Robillard JM; Rice JJ; Soares H; Tome MB; Tarnanas I; Vargas G; Bain LJ; Czaja SJ Alzheimers Dement (N Y); 2018; 4():234-242. PubMed ID: 29955666 [TBL] [Abstract][Full Text] [Related]
2. Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review. Piau A; Wild K; Mattek N; Kaye J J Med Internet Res; 2019 Aug; 21(8):e12785. PubMed ID: 31471958 [TBL] [Abstract][Full Text] [Related]
3. Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. Kaye J; Aisen P; Amariglio R; Au R; Ballard C; Carrillo M; Fillit H; Iwatsubo T; Jimenez-Maggiora G; Lovestone S; Natanegara F; Papp K; Soto ME; Weiner M; Vellas B J Prev Alzheimers Dis; 2021; 8(4):513-519. PubMed ID: 34585227 [TBL] [Abstract][Full Text] [Related]
4. Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work. Andriesen J; Bull S; Dietrich J; Haberer JE; Van Der Pol B; Voronin Y; Wall KM; Whalen C; Priddy F J Med Internet Res; 2017 Jul; 19(7):e274. PubMed ID: 28760729 [TBL] [Abstract][Full Text] [Related]
5. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools? Snyder PJ; Kahle-Wrobleski K; Brannan S; Miller DS; Schindler RJ; DeSanti S; Ryan JM; Morrison G; Grundman M; Chandler J; Caselli RJ; Isaac M; Bain L; Carrillo MC Alzheimers Dement; 2014 Nov; 10(6):853-60. PubMed ID: 25458309 [TBL] [Abstract][Full Text] [Related]
6. Measuring cognition and function in the preclinical stage of Alzheimer's disease. Weintraub S; Carrillo MC; Farias ST; Goldberg TE; Hendrix JA; Jaeger J; Knopman DS; Langbaum JB; Park DC; Ropacki MT; Sikkes SAM; Welsh-Bohmer KA; Bain LJ; Brashear R; Budur K; Graf A; Martenyi F; Storck MS; Randolph C Alzheimers Dement (N Y); 2018; 4():64-75. PubMed ID: 29955653 [TBL] [Abstract][Full Text] [Related]
7. Review of information and communication technology devices for monitoring functional and cognitive decline in Alzheimer's disease clinical trials. Pillai JA; Bonner-Jackson A J Healthc Eng; 2015; 6(1):71-83. PubMed ID: 25708378 [TBL] [Abstract][Full Text] [Related]
9. Editorial: Can Digital Technology Advance the Development of Treatments for Alzheimer's Disease? Mc Carthy M; Schueler P J Prev Alzheimers Dis; 2019; 6(4):217-220. PubMed ID: 31686090 [TBL] [Abstract][Full Text] [Related]
12. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease. Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115 [TBL] [Abstract][Full Text] [Related]
13. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Mattsson N; Carrillo MC; Dean RA; Devous MD; Nikolcheva T; Pesini P; Salter H; Potter WZ; Sperling RS; Bateman RJ; Bain LJ; Liu E Alzheimers Dement (Amst); 2015 Dec; 1(4):412-9. PubMed ID: 27239522 [TBL] [Abstract][Full Text] [Related]
14. Remote Digital Technologies for the Early Detection and Monitoring of Cognitive Decline in Patients With Type 2 Diabetes: Insights From Studies of Neurodegenerative Diseases. DuBord AY; Paolillo EW; Staffaroni AM J Diabetes Sci Technol; 2023 Apr; ():19322968231171399. PubMed ID: 37102472 [TBL] [Abstract][Full Text] [Related]
16. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers? Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082 [TBL] [Abstract][Full Text] [Related]
17. Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity. Kourtis LC; Regele OB; Wright JM; Jones GB NPJ Digit Med; 2019; 2():. PubMed ID: 31119198 [TBL] [Abstract][Full Text] [Related]
18. Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Rabinovici GD; Carrillo MC; Forman M; DeSanti S; Miller DS; Kozauer N; Petersen RC; Randolph C; Knopman DS; Smith EE; Isaac M; Mattsson N; Bain LJ; Hendrix JA; Sims JR Alzheimers Dement (N Y); 2017 Jan; 3(1):83-91. PubMed ID: 29067320 [TBL] [Abstract][Full Text] [Related]